HealthQuill FDA
A bacteria that causes infections, including pneumonia, bloodstream infections, and meningitis are being treated by doctors with less effective old generic antibiotics ā€” even though the US regulator has cleared seven next-generation antibiotics to deal with the germs.
Drugs Health Pharma

US doctors still prescribe old generic antibiotics, cost main factor

HQ Team April 20, 2024: A bacteria that causes infections, including pneumonia, bloodstream infections, and meningitis are being treated by doctors with less.

Read More
Anglo-Swedish drugmaker, AstraZeneca will acquire clinical-stage Fusion Pharmaceuticals for $2 billion in cash to get access to the latterā€™s radioconjugates to treat cancer.
Drugs Medical Pharma

FDAā€™s accelerated approval of cancer drugs is hasty and doubtful, says new report

HQ Team April 10, 2024:Ā  A new study has found that cancer drugs that got accelerated approval under the US Federal Drug Approval.

Read More
Amylyx Pharmaceuticals announced it has started a process with the USFDA and Health Canada to voluntarily discontinue the marketing authorisations for its amyotrophic lateral sclerosis (ALS) therapy after the drug failed in a last-stage trial.
Drugs Health Pharma

Amylyx Pharma pulls out ALS therapy drug from US, Canada

HQ Team April 4, 2024: Amylyx Pharmaceuticals announced it has started a process with the USFDA and Health Canada to voluntarily discontinue the.

Read More
The USFDA approved Swiss-based Basilea Pharmaceutica Internationalā€™s Zevtera injection for the treatment of staphylococcus aureus bloodstream infections and skin infections in adults and community-acquired bacterial pneumonia in patients three months to 18 years, and adults.Ā 
Drugs Health Pharma

Swiss-based Basilea Pharmaceuticalā€™s antimicrobial drug gets FDA nodĀ 

HQ Team April 4, 2024: The USFDA approved Swiss-based Basilea Pharmaceutica Internationalā€™s Zevtera injection for the treatment of staphylococcus aureus bloodstream infections and.

Read More
The US regulator, the Food and Drug Administration plans to ban electrical stimulation devices due to ā€œunreasonable and substantial riskā€ of illness or injury.
Drugs Medical Pharma

FDA attempts a second time to ban electrical stimulation devices

HQ Team March 26, 2024: The US regulator, the Food and Drug Administration plans to ban electrical stimulation devices due to ā€œunreasonable and.

Read More
The US Food and Drug Administration has cleared Orchard Therapeuticsā€™s gene therapy to treat a disease affecting the brain and nervous system in children ā€” the regulatorā€™s first ever for the disorder.
Drugs Health Pharma

FDA green lights first-ever therapy for rare genetic disease in kids

HQ Team March 19, 2023: The US Food and Drug Administration has cleared Orchard Therapeuticsā€™s gene therapy to treat a disease affecting the.

Read More
Pfizer Inc., announced that a late-stage study on its Adcetris drug, for treating the most common lymphoma, yielded positive results and improved overall survival rates.
Drugs Health Pharma

Pfizer says trials on lymphoma drug ā€˜positive,ā€™ extends life of patientsĀ 

HQ Team March 12, 2024: Pfizer Inc., announced that a late-stage study on its Adcetris drug, for treating the most common lymphoma, yielded.

Read More
The FDA has issued revised draft guidance for early treatment of Alzheimerā€™s disease with drugmakers told to focus on medicines that are likely to predict a clinical benefit.
Drugs Health Pharma

FDA issues revised drug guidelines for early Alzheimerā€™s disease

HQ Team March 12, 2024: The FDA has issued revised draft guidance for early treatment of Alzheimerā€™s disease with drugmakers told to focus.

Read More
The FDA has approved Pfizerā€™s Besponsa drug for pediatric patients aged one year and above to treat acute leukaemia.
Drugs Health Pharma

Pfizerā€™s pediatric leukaemia drug gets regulator FDA’s green light

HQ Team March 7, 2024: The FDA has approved Pfizerā€™s Besponsa drug for pediatric patients aged one year and above to treat acute.

Read More
Bayer AG, a German multinational pharmaceutical and biotechnology company, has bought the marketing rights in Europe for a heart drug for $310 million to expand its cardiology portfolio.
Drugs Health Pharma

Bayer acquires marketing rights for heart drug in Europe for $310 million

HQ Team March 4, 2024: Bayer AG, a German multinational pharmaceutical and biotechnology company, has bought the marketing rights in Europe for a.

Read More